Shanghai Pharmaceuticals' subsidiary SPH Sine has received a drug registration certificate from the National Medical Products Administration for Omeprazole and Sodium Bicarbonate for Oral Suspension (I), granting approval for production. The drug is primarily used for the short-term treatment of active duodenal ulcers and gastroesophageal reflux disease. Shanghai Pharmaceuticals stated that the approval will help expand its market share, but sales remain uncertain due to policy and market conditions, and reminded investors to be aware of the risks.
Shanghai Pharmaceuticals Holding Co LtdDrug registration certificate approved for production, expanding market share.
Subsidiary SPH Sine received approval for production of the drug.